Update date: Jul 08, 2026 | 100 Pages | Report ID: HO-003603
Pharmaceutical Contract Manufacturing Market
DMA IntelligencePharmaceutical Contract Manufacturing Growth Drivers & Forecast Analysis 2033
Segments: Product (Prefilled Syringes, Vials, Cartridges, Others), Molecule (Large Molecules, Small Molecules), End Use (Biopharmaceutical Companies, Pharmaceutical Companies), By Region, And Segment Forecasts
$40.0B
Market Size, 2025
$43.2B
Market Estimate, 2026
$74.0B
Market Forecast, 2033
8.0%
CAGR, 2026–2033
Pharmaceutical Contract Manufacturing Market Size, Share & Key Insights
The Pharmaceutical Contract Manufacturing Market size was valued at USD 40.00 Billion in 2025, and the market is projected to grow from USD 43.20 Billion in 2026 to USD 74.04 Billion by 2033, growing at a CAGR of 8% during the forecast period 2026–2033. The market saw distributed global demand in 2025.
Study Overview
 Study Period | 2021 - 2033 |
 Base Year | 2025 |
 Estimated Year | 2026 |
 Forecast Period | 2026-2033 |
 Historical Range | 2021-2025 |
| Units | USD Billion |
 Coverage | Global | North America, Europe, Asia-Pacific, Latin America, Middle East & Africa |
 Deliverables | PDF + Excel Data Pack |
Major Market Players
Key Insights
- The global Pharmaceutical Contract Manufacturing market is projected to grow from USD 40.00 Billion in 2025 to USD 74.01 Billion by 2033, exhibiting a robust CAGR of 8.00% during the forecast period, underscoring sustained demand for outsourced services.
- North America currently holds the largest market share in pharmaceutical contract manufacturing, primarily due to its advanced pharmaceutical infrastructure, high R&D investments, and stringent regulatory environment driving outsourcing needs.
- Asia Pacific is identified as the fastest-growing market segment, fueled by rising healthcare expenditure, expanding manufacturing capabilities, and a growing number of local pharmaceutical companies leveraging cost-effective production services.
- Active Pharmaceutical Ingredients (APIs) Manufacturing is expected to retain its leading position within the market segmentation, driven by increasing demand for generic drugs and complex APIs, requiring specialized synthesis expertise from CMOs.
Market Definition and Strategic Context
The Pharmaceutical Contract Manufacturing Market refers to the outsourcing of various drug development and manufacturing activities by pharmaceutical companies to third-party contract manufacturing organizations (CMOs) or contract development and manufacturing organizations (CDMOs). This encompasses a wide range of services, including active pharmaceutical ingredient (API) manufacturing, finished dose formulation (FDF), packaging, and analytical testing. The global Pharmaceutical Contract Manufacturing market size was valued at USD 40.00 Billion in 2025 and is poised for significant industry expansion, driven by factors such as increasing R&D expenditure, the growing complexity of drug development, and the need for specialized manufacturing capabilities. The market is projected to witness robust growth outlook as pharmaceutical companies increasingly focus on core competencies, leveraging CMOs for cost efficiency, scalability, and access to advanced technologies. This strategic shift is expected to propel the market forecast, fostering innovation and enhancing the overall efficiency of the pharmaceutical supply chain. The industry's growth trajectory is also influenced by stringent regulatory requirements, which CMOs are well-equipped to navigate, offering a compliant and efficient path for drug production. As the pipeline of novel therapies, particularly biologics and advanced cell and gene therapies, continues to expand, the demand for specialized contract manufacturing services is anticipated to surge, contributing to the sustained growth of this vital sector.
| Report Attribute | Details |
|---|---|
| Market size value in 2025 | USD 40.00 Billion |
| Revenue forecast in 2033 | USD 74.04 Billion |
| Growth rate | CAGR of 8% from 2025 to 2033 |
| Actual data | 2021 - 2024 |
| Forecast period | 2025 - 2033 |
| Quantitative units | Revenue in USD Billion and CAGR from 2025 to 2033 |
| Report coverage | Revenue forecast, company share, competitive landscape, growth factors, and trends |
| Segments covered | Product, Molecule, End Use |
| Regional scope | UK; Germany; France; Italy; Spain; Denmark; Sweden; Norway |
| Country scope | All; All; All; All; All; All; All; All |
| Key companies profiled | Thermo Fisher Scientific Inc; Sartorius AG; Boehringer Ingelheim International GmbH; Catalent, Inc (acquired by Novo Holdings A/S); Societal CDMO (Recro Pharma, Inc); Baxter; Eurofins Scientific; Symbiosis Pharmaceutical Services Ltd; MabPlex International Co. Ltd; Recipharm AB; Fresenius Kabi, USA LLC; Lonza |
| Customization scope | Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. Explore purchase options |
Growth Catalysts & Market Constraints
The Pharmaceutical Contract Manufacturing market is experiencing dynamic shifts, influenced by a confluence of growth catalysts and inherent constraints. The increasing complexity of drug molecules, coupled with the rising cost of in-house manufacturing, is compelling pharmaceutical companies to leverage specialized CMO expertise. This strategic outsourcing trend significantly contributes to the Pharmaceutical Contract Manufacturing market size, driving its growth forecast. Furthermore, the growing demand for biologics and personalized medicines necessitates advanced manufacturing technologies and regulatory compliance, which CMOs are well-positioned to provide. However, challenges related to intellectual property protection and supply chain complexities can temper this expansion, requiring careful navigation by market players to ensure sustainable industry growth.
Growth Drivers
- Increasing R&D expenditure and the growing pipeline of complex drug candidates, particularly biologics and biosimilars, are driving pharmaceutical companies to outsource specialized manufacturing processes. CMOs offer the necessary expertise, advanced technologies, and regulatory compliance, reducing the capital investment and operational burden for drug innovators while accelerating time-to-market.
- The rising demand for cost-effective manufacturing solutions and the need for scalability to meet fluctuating market demands are compelling pharmaceutical firms to partner with contract manufacturers. CMOs provide economies of scale, access to global supply chains, and flexible production capacities, enabling companies to optimize their operational costs and respond efficiently to market shifts without significant in-house infrastructure investments.
Restraints
- Concerns regarding intellectual property (IP) protection and data security act as a significant restraint, as pharmaceutical companies are hesitant to share proprietary drug formulations and manufacturing processes with third-party vendors. This risk of IP infringement or unauthorized disclosure can deter outsourcing, particularly for highly innovative or blockbuster drugs, thereby limiting market expansion.
- Maintaining consistent quality control and ensuring regulatory compliance across multiple contract manufacturing sites globally presents a substantial challenge. Discrepancies in manufacturing standards or regulatory interpretations between different CMOs can lead to product recalls, delays in market approval, and reputational damage, increasing the operational burden for pharmaceutical clients.
Opportunities
- Expansion into emerging markets, such as Asia Pacific and Latin America, offers significant growth opportunities for CMOs, driven by increasing healthcare access, rising pharmaceutical consumption, and supportive government initiatives. Establishing manufacturing facilities or strategic partnerships in these regions can tap into a rapidly growing customer base and leverage lower operational costs.
- The adoption of advanced manufacturing technologies, including continuous manufacturing, single-use systems, and automation, presents an opportunity for CMOs to enhance efficiency, reduce production costs, and offer specialized services. Investing in these innovations can differentiate providers and attract pharmaceutical clients seeking cutting-edge solutions for complex drug development and production.
Challenges
- Intensifying competition and pricing pressures from a growing number of CMOs, particularly in mature markets, pose a significant challenge. This competitive landscape forces providers to continually optimize costs and differentiate services, often leading to reduced profit margins and increased pressure to secure long-term contracts, impacting overall market stability.
- Managing complex supply chains, including raw material sourcing, logistics, and inventory management across multiple geographies, remains a critical challenge. Disruptions due to geopolitical events, natural disasters, or quality issues can severely impact production timelines and drug availability, requiring robust risk mitigation strategies and diversified supplier networks.
Market Level Breakdown
The Pharmaceutical Contract Manufacturing market is comprehensively segmented by Product, Molecule, and End Use, providing a granular view of its diverse operational landscape. The Product segment primarily includes Active Pharmaceutical Ingredients (APIs) Manufacturing, Finished Dose Formulation (FDF) Manufacturing, Biologics Manufacturing, and Packaging & Labeling. API manufacturing constitutes a significant portion of the market due to the increasing complexity of synthesizing active drug components and the rising demand for generic drugs globally, driving outsourcing to specialized CMOs. FDF manufacturing covers the conversion of APIs into final dosage forms like tablets, capsules, and injectables, requiring advanced capabilities and adherence to stringent quality standards. Biologics manufacturing is a rapidly expanding segment, driven by the growth of biopharmaceuticals and advanced therapies that demand specialized and often costly production infrastructure. Packaging & Labeling services ensure the safe and compliant delivery of pharmaceutical products to market. This comprehensive Pharmaceutical Contract Manufacturing segmentation underscores the varied expertise required across the drug lifecycle.
Further market taxonomy is provided by the Molecule segment, which differentiates between Small Molecules and Biologics. Small molecules, traditionally the backbone of the pharmaceutical industry, continue to represent a larger share of outsourced manufacturing due to their established production processes and high volume requirements. However, the Biologics segment is experiencing rapid growth, fueled by breakthrough therapies in oncology, immunology, and rare diseases. Manufacturing biologics is inherently more complex and capital-intensive, involving living organisms and requiring specialized facilities, which makes outsourcing an attractive option for many pharmaceutical and biopharmaceutical companies. This shift towards biologics is a key trend shaping the future of the Pharmaceutical Contract Manufacturing market.
The End Use segment categorizes the market by the primary clients of CMOs, including Pharmaceutical Companies, Biopharmaceutical Companies, and Academic & Research Institutions. Pharmaceutical companies, both large and small, are the primary drivers of demand for contract manufacturing services, seeking to streamline operations, reduce costs, and access advanced technologies. Biopharmaceutical companies, often specializing in complex protein-based drugs, rely heavily on CMOs for their specialized manufacturing capabilities and regulatory expertise. Academic and research institutions also leverage contract manufacturers for early-stage drug development, clinical trial material production, and specialized analytical services, contributing to the overall industry expansion and market growth.
Pharmaceutical Contract Manufacturing Segmentation Breakdown
- Product
- Prefilled Syringes
- Vials
- Cartridges
- Others
- Molecule
- Large Molecules
- Small Molecules
- End Use
- Biopharmaceutical Companies
- Pharmaceutical Companies
Geographic Performance & Regional Trends
North America currently dominates the Pharmaceutical Contract Manufacturing market, holding the largest share in 2025, primarily due to the presence of a robust pharmaceutical industry, significant R&D investments, and stringent regulatory frameworks that encourage outsourcing. The region benefits from a high concentration of biopharmaceutical companies and advanced manufacturing capabilities. Conversely, Asia Pacific is emerging as the fastest-growing market, driven by increasing healthcare expenditure, expanding local pharmaceutical manufacturing bases, and favorable government initiatives promoting drug production. This Pharmaceutical Contract Manufacturing market growth in Asia Pacific is largely attributable to lower operational costs, a skilled workforce, and a growing patient population, making it an attractive hub for global pharmaceutical companies seeking to expand their manufacturing footprint.
Regional Growth Drivers
- North America: The region's robust pharmaceutical and biotechnology sector, coupled with high R&D spending and a strong emphasis on innovative drug development, drives significant outsourcing demand. Companies in the United States and Canada frequently partner with CMOs to access specialized technologies, accelerate drug development timelines, and navigate complex regulatory pathways, thereby sustaining market leadership.
- Europe: Stringent regulatory requirements from the European Medicines Agency (EMA) and a mature pharmaceutical industry encourage outsourcing to specialized CMOs capable of ensuring compliance and quality. Countries like Germany, the United Kingdom, and France benefit from established infrastructure and a highly skilled workforce, fostering consistent demand for contract manufacturing services, particularly for complex biologics.
- Asia Pacific: Rapid economic development, rising healthcare expenditure, and a growing patient population significantly boost pharmaceutical production in countries like China, India, and Japan. The region offers cost-effective manufacturing solutions, a large pool of scientific talent, and increasing government support for domestic pharmaceutical industries, attracting global companies for both local and export markets.
- Latin America: Modernization of healthcare infrastructure and increasing access to advanced medicines are driving pharmaceutical market growth in countries such as Brazil and Mexico. Local pharmaceutical companies are increasingly outsourcing manufacturing to enhance efficiency and meet growing demand, while foreign companies establish a presence to tap into the region's expanding patient base and emerging market opportunities.
- Middle East & Africa: Efforts to diversify economies away from oil, coupled with investments in healthcare infrastructure and increasing access to essential medicines, are stimulating the pharmaceutical sector. Countries like Saudi Arabia and South Africa are focusing on local drug production and technology transfer, creating opportunities for CMO partnerships to build manufacturing capabilities and ensure drug security in the region.
The regional forecast indicates continued growth across all geographies, albeit with varying paces. Mature markets in North America and Europe are expected to maintain steady growth, driven by innovation in complex biologics and advanced therapies, alongside ongoing cost-optimization strategies. Emerging markets in Asia Pacific and Latin America will likely experience more rapid expansion, fueled by increasing healthcare access, rising disposable incomes, and the establishment of new manufacturing hubs. For suppliers, this implies a need for localized strategies, including potential partnerships and investments in regional facilities, to capitalize on diverse market dynamics and regulatory landscapes, balancing the stability of established markets with the high-growth potential of developing regions.
Competitive Insights & Leading Companies
The Pharmaceutical Contract Manufacturing competitive landscape is characterized by a moderately consolidated structure, featuring a mix of large, diversified global players and numerous specialized regional CMOs. Global leaders often possess extensive capabilities across the entire drug development and manufacturing spectrum, from API synthesis to finished product packaging, catering to a wide range of therapeutic areas. Regional players, on the other hand, typically focus on niche services, specific dosage forms, or localized markets, leveraging their proximity and understanding of regional regulatory nuances. Key competitive levers in this market include technological expertise, particularly in complex areas like biologics and high-potency APIs, regulatory compliance track record, cost-efficiency, and the ability to offer integrated end-to-end services. Pricing strategies are highly competitive, driven by the need to secure long-term contracts, while strong distribution networks and supply chain reliability are crucial for timely product delivery. Regulatory approvals and certifications from major health authorities like the FDA and EMA are paramount, serving as critical differentiators and barriers to entry for new players.
Strategic differentiation in the Pharmaceutical Contract Manufacturing market is achieved through various approaches. Many leading players are pursuing inorganic growth strategies, including mergers and acquisitions, to expand their service portfolios, geographical reach, and technological capabilities. For instance, the acquisition of Catalent by Novo Holdings A/S highlights the trend towards consolidating specialized capabilities. Partnerships and collaborations are also prevalent, enabling companies to share risks, access new markets, and develop innovative solutions. Product launches often focus on introducing advanced manufacturing techniques or specialized capacities for novel drug modalities. R&D investments are critical for developing proprietary technologies and improving process efficiency, offering clients enhanced value. Localization strategies, such as establishing facilities in emerging markets, help companies tap into new demand centers and navigate regional supply chain complexities. However, the industry faces challenges like margin pressure due to intense competition, high compliance costs associated with evolving regulations, and the risk of commoditization for standard manufacturing services. Supply chain risks, including raw material shortages and geopolitical disruptions, also necessitate robust mitigation strategies to maintain operational continuity and client trust, driving continuous innovation and strategic adaptation among key players.
Pharmaceutical Contract Manufacturing Key Companies
- Thermo Fisher Scientific Inc
- Sartorius AG
- Boehringer Ingelheim International GmbH
- Catalent, Inc (acquired by Novo Holdings A/S)
- Societal CDMO (Recro Pharma, Inc)
- Baxter
- Eurofins Scientific
- Symbiosis Pharmaceutical Services Ltd
- MabPlex International Co. Ltd
- Recipharm AB
- Fresenius Kabi, USA LLC
- Lonza
Pharmaceutical Contract Manufacturing Market Ecosystem
Ecosystem Participants
- Pharmaceutical and Biopharmaceutical Companies — These entities are the primary clients of CMOs, outsourcing drug discovery, development, and manufacturing processes. They seek specialized expertise, cost efficiencies, and scalability to bring new drugs to market faster while focusing on their core competencies of research and commercialization.
- Their operational responsibilities include drug innovation, clinical trials management, and market access strategies, while relying on CMOs for compliant and efficient production, reducing their capital expenditure and operational risks.
- Contract Manufacturing Organizations (CMOs)/Contract Development and Manufacturing Organizations (CDMOs) — These are the core service providers offering a comprehensive range of services from API synthesis, formulation development, clinical trial material manufacturing, to commercial production, packaging, and analytical testing. They possess specialized facilities, technologies, and regulatory expertise.
- CMOs provide critical support by enabling clients to navigate complex manufacturing challenges, scale production, and meet stringent regulatory requirements across diverse therapeutic areas, forming strategic partnerships that extend beyond simple vendor relationships.
- Raw Material and Equipment Suppliers — These participants provide essential components, chemicals, excipients, and advanced manufacturing equipment necessary for drug production. Their reliability, quality, and supply chain integrity are crucial for the seamless operation of CMOs and their pharmaceutical clients.
- Ensuring a consistent supply of high-quality raw materials and state-of-the-art equipment directly impacts the efficiency, cost-effectiveness, and regulatory compliance of the entire drug manufacturing process.
- Regulatory Bodies and Government Agencies — Organizations like the FDA, EMA, and other national health authorities establish and enforce regulations governing drug development, manufacturing, and quality control. Their oversight ensures product safety, efficacy, and compliance with Good Manufacturing Practices (GMP).
- These bodies are crucial for setting industry standards, conducting inspections, and approving drug products, thereby influencing manufacturing processes, quality systems, and market entry strategies for both pharmaceutical companies and CMOs.
- Logistics and Supply Chain Providers — These companies specialize in the transportation, storage, and distribution of raw materials, intermediate products, and finished pharmaceutical goods. They play a vital role in ensuring timely and secure delivery across global supply chains, often handling temperature-sensitive and high-value products.
- Effective logistics management is essential for minimizing risks associated with product integrity, maintaining cold chain requirements, and ensuring efficient distribution from manufacturing sites to end-markets.
Report Coverage & Key Deliverables
The report delivers a comprehensive analysis of the Pharmaceutical Contract Manufacturing, combining quantitative data with qualitative insights to provide a holistic understanding of the market landscape. This meticulous research aims to equip stakeholders, including pharmaceutical companies, CMOs, investors, and regulatory bodies, with actionable intelligence for strategic decision-making. It delves into the market's historical performance, current trends, and future projections, offering a clear trajectory of growth opportunities and potential challenges. The study encompasses a detailed examination of market drivers, restraints, opportunities, and competitive dynamics, ensuring that readers can identify key factors influencing industry evolution. By integrating in-depth market sizing, segmentation analysis, and competitive benchmarking, the report serves as an invaluable resource for assessing market attractiveness, formulating expansion strategies, and optimizing operational efficiencies. Its scope is designed to provide clarity on market structure, technological advancements, and regional disparities, enabling a nuanced understanding of the global Pharmaceutical Contract Manufacturing ecosystem and empowering informed business strategies.
Report Coverage
- Market Size Estimates (historical and forecast)
- Our market size estimates cover a comprehensive historical period from 2021 to 2025, providing a robust foundation for understanding past performance. The forecast extends from 2026 to 2033, utilizing advanced statistical models and industry expert insights to project future growth. This methodology ensures accuracy and reliability in predicting market trajectories, aiding strategic planning.
- Detailed Segmentation And Revenue Analysis
- The report provides an exhaustive breakdown of the market by product type (APIs, FDF, Biologics, Packaging), molecule type (Small Molecules, Biologics), and end-use (Pharmaceutical Companies, Biopharmaceutical Companies, Academic & Research Institutions). Each segment's revenue contribution and growth prospects are meticulously analyzed, offering insights into key monetization lenses and high-potential areas for investment.
- Regional And Country-Level Insights
- We offer in-depth analysis across major geographies including North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, with further breakdown at the country level. This regional coverage highlights market maturity, growth disparities, and unique regulatory landscapes, providing a comparative context for international expansion strategies and localized market approaches.
- Competitive Benchmarking Of Key Players
- A thorough competitive landscape assessment profiles leading companies in the Pharmaceutical Contract Manufacturing market, evaluating their strategic positioning, product portfolios, and recent developments. This section identifies key differentiators, market shares, and competitive strategies, enabling stakeholders to benchmark their performance and identify partnership opportunities or competitive threats.
- Customization Options Based on Specific Requirements
- Clients can avail customization options equivalent to 8 analyst working days with the purchase of the report. This flexibility allows for tailoring the scope to specific needs, including the addition or alteration of country, regional, or segment analysis. Our aim is to provide deliverables that directly address unique business intelligence requirements, enhancing the report's utility.
Recent Industry Insights
The Pharmaceutical Contract Manufacturing industry trends over the last 12-18 months reflect a strong emphasis on expanding biologics manufacturing capacity and strategic partnerships. Companies are increasingly investing in advanced technologies like continuous manufacturing and single-use systems to enhance efficiency and flexibility. There's also a noticeable shift towards integrated CDMO models, offering end-to-end services from drug discovery to commercial manufacturing, to streamline processes for clients. Regulatory changes, particularly around quality control and supply chain resilience, continue to shape operational strategies, pushing CMOs to strengthen their compliance frameworks. Furthermore, growing demand for cell and gene therapies is spurring specialized investments, creating new opportunities for contract manufacturers capable of handling these complex modalities, thereby driving innovation and market growth.
Key Market Developments
- November 2024: Lonza announced a significant expansion of its biologics manufacturing facility in Switzerland to meet the growing demand for mammalian-derived biopharmaceuticals, enhancing its capacity for clinical and commercial production.
- September 2024: Catalent, Inc (now acquired by Novo Holdings A/S) entered into a strategic partnership with a leading biotech firm to accelerate the development and manufacturing of a novel gene therapy candidate, leveraging Catalent's specialized fill/finish capabilities.
- July 2024: Thermo Fisher Scientific Inc launched a new integrated CDMO solution aimed at simplifying the drug development and manufacturing process for small and emerging biopharma companies, offering comprehensive services from discovery to commercialization.
- May 2024: Recipharm AB announced the acquisition of a sterile injectable manufacturing site in France, significantly bolstering its capabilities in aseptic filling and expanding its European footprint for complex formulations.
- March 2024: The United States FDA introduced new guidance on advanced manufacturing technologies, encouraging pharmaceutical companies and CMOs to adopt innovative approaches to enhance drug quality and supply chain resilience.
- January 2024: Sartorius AG expanded its portfolio of single-use bioprocessing solutions, aiming to support CMOs in improving efficiency and reducing the risk of cross-contamination in biologics manufacturing.
Analyst Opinion
The Pharmaceutical Contract Manufacturing market outlook remains highly attractive, driven by an accelerating trend of outsourcing across the pharmaceutical and biopharmaceutical sectors. The market's attractiveness stems from the increasing complexity of drug molecules, the high capital investment required for in-house manufacturing, and the need for specialized expertise in areas like biologics and advanced therapies. The competitive intensity is moderately consolidated, with large global players leveraging their comprehensive service offerings and technological prowess, while specialized regional CMOs carve out niche markets. This dynamic creates a healthy balance between competition and collaboration, fostering innovation. The demand-supply balance is currently favorable for CMOs, particularly for those with capabilities in high-growth segments such as biologics and sterile injectables, indicating sustained growth potential. However, the industry must continuously adapt to evolving regulatory landscapes and client demands for greater transparency and flexibility in service delivery. Strategic partnerships and M&A activities are expected to continue shaping the competitive landscape, as companies seek to expand their geographic reach and enhance their technological portfolios.
Looking ahead, the long-term outlook for the Pharmaceutical Contract Manufacturing market is robust, underpinned by a consistent pipeline of novel drug candidates and the increasing adoption of personalized medicine. The innovation landscape is thriving, with significant advancements in continuous manufacturing, AI-driven process optimization, and specialized facilities for cell and gene therapies. These technological shifts will enable CMOs to offer more efficient, cost-effective, and higher-quality services, further solidifying their role in the pharmaceutical value chain. Key risk factors include geopolitical instability impacting global supply chains, the inherent challenges of intellectual property protection, and intense pricing pressures in certain segments. Additionally, the rapid pace of scientific discovery necessitates continuous investment in R&D and workforce training to maintain a competitive edge. Strategic implications for market participants involve a focus on vertical integration, diversification into high-growth therapeutic areas, and investing in digital transformation to enhance operational agility and client engagement. CMOs that can offer integrated, flexible, and technologically advanced solutions will be best positioned to capitalize on future growth opportunities and mitigate emerging risks effectively.